Tecan to expand U.S. pipette tip manufacturing in response to COVID-19

Tecan supports expansion of U.S. pipette tip manufacturing for COVID-19 testing with $32.9M investment from U.S. government
Mannedov, Switzerland, October 27, 2020 – Tecan Group (SWX: TECN) today announced that the US Department of Defense (DoD) and the US Department of Health and Human Services (HHS) awarded $32.9 million ($29.8 CHF) million) contract to support U.S. accumulation of pipette tip manufacturing for COVID-19 testing.Disposable pipette tips are a key component of SARS-CoV-2 molecular testing and other assays performed on fully automated, high-throughput systems.
The manufacturing equipment used to produce these pipette tips is highly specialized, requiring fully automated production lines capable of precise molding and multiple in-line visual quality tests.The funding will support Tecan in launching new production capacity in the United States by expediting the process.The contract award is part of an ongoing collaboration between the Department of Defense and HHS, led by the Department of Defense Joint Acquisition Task Force (JATF) and funded through the CARES Act, to support and support the expansion of the domestic industrial base for critical medical resources.The new U.S. production line is expected to begin production of pipette tips in fall 2021, supporting an increase in domestic testing capacity to millions of tests per month by December 2021.The expansion of U.S. production will reinforce the steps Tecan has already taken to increase global manufacturing capacity at other locations, doubling Tecan’s global pipette tip production capacity, with production expected to increase further in early 2021.
“Testing is one of the most important tools in the fight against the global COVID-19 pandemic; doing this quickly, efficiently and consistently requires excellent clinical expertise and a high-quality technical system,” said Tecan CEO Dr. Achim von Leoprechting Say.”We’re proud that Tecan’s automated solutions – and the disposable pipette tips they need – are a critical part of the process. This government-funded investment in expanding U.S. manufacturing capabilities is a key part of our laboratory and diagnostic testing collaborations. It’s very important for partners and public health.”
Tecan is a pioneer and global market leader in laboratory automation.The company’s laboratory automation solutions help laboratories automate diagnostic tests and make procedures more precise, efficient, and safer.By automating testing, laboratories can significantly increase the sample size they process, get test results faster and ensure accurate output.Tecan directly serves some customers such as large clinical reference laboratories, but also provides OEM instruments and pipette tips to diagnostic companies as a total solution to use with their associated test kits.
About Tecan Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions for biopharmaceuticals, forensics and clinical diagnostics.The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences.Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories.As an Original Equipment Manufacturer (OEM), Tecan is also a leader in the development and manufacture of OEM instruments and components, which are then distributed by partner companies.Founded in Switzerland in 1980, the company has manufacturing, R&D sites in Europe and North America, and a sales and service network in 52 countries.In 2019, Tecan’s sales were CHF 637 million (USD 643 million; EUR 574 million).The registered shares of Tecan Group are traded on six Swiss exchanges (TECN; ISIN CH0012100191).
Martin Brändle Senior Vice President, Corporate Communications and IRTel, Tecan Group.+41 (0) 44 922 84 30 Fax +41 (0) 44 922 88 89investor@tecan.comwww.tecan.com

Post time: Jun-10-2022